Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

InterDigital Announces Date for Second Quarter 2024 Financial Results

InterDigital, Inc. WILMINGTON, Del., July 18, 2024 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that the company will release its second quarter 2024 financial results before the market open on Thursday, August …

EODHD | 18 July 2024

Home Prices Advance Another 3 Percent in Second Quarter, Show Signs of Slowing

Latest FNM-HPI Reading Showed Year-over-Year Increase of 6.9 Percent in Q2 2024 WASHINGTON, July 18, 2024 /PRNewswire/ -- Single-family home prices increased 6.9 percent from Q2 2023 to Q2 2024, down from the previous quarter's upwardly revised annual growth rate of 7.3 percent, according …

EODHD | 18 July 2024

Overstock.com Announces Grand Reopening

—Management Encouraged by Accelerating Revenue Run-Rate in First 90 Days — — New Categories Including Closeouts, Liquidation, Reverse Logistics, and Factory Direct, in Addition to Core Legacy Categories, Drive Growth Plan — MIDVALE, Utah, July 18, 2024--(BUSINESS WIRE)--Beyond, Inc. (NYSE:BYON), owner of Overstock, Bed …

EODHD | 18 July 2024

CSG Forte Wins TSG Award for Best API Set Second Year in a Row

Named a Leader in the 2024 Best of Breed API Awards and recognized for creating a user-friendly experience for developers DENVER, July 18, 2024--(BUSINESS WIRE)--TSG (The Strawhecker Group) recognized CSG Forte, a leader in complete and customizable digital payment solutions, as the Best API …

EODHD | 18 July 2024

First Solar Commissions Western Hemisphere’s Largest Solar R&D Center

First Solar today commissioned a new research and development (R&D) innovation center in Lake Township, Ohio, believed to be the largest facility of its kind in the Western Hemisphere. The facility covers 1.3 million square feet and includes a high-tech pilot manufacturing line allowing …

EODHD | 18 July 2024

Hilltop Holdings Inc. Announces Second Quarter 2024 Earnings Conference Call and Webcast

DALLAS, July 18, 2024--(BUSINESS WIRE)--Hilltop Holdings Inc. (NYSE: HTH) ("Hilltop"), a Dallas-based financial holding company, will host a live webcast and conference call at 8:00 AM Central (9:00 AM Eastern) on Friday, July 26, 2024. Hilltop President and CEO Jeremy B. Ford and Hilltop …

EODHD | 18 July 2024

Michelin: Initiation rating from Scope Ratings and upgrade from Moody’s Ratings

Michelin Clermont-Ferrand, July 18, 2024 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Initiation rating from Scope Ratings and upgrade from Moody’s Ratings On July 12, 2024, the European rating agency Scope Ratings published a solicited rating report on Michelin (Compagnie Générale des Etablissements Michelin and its …

EODHD | 18 July 2024

MGP Ingredients to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

MGP Ingredients ATCHISON, Kan., July 18, 2024 (GLOBE NEWSWIRE) -- MGP Ingredients, Inc. (NASDAQ:MGPI), a leading provider of branded and distilled spirits and food ingredient solutions, today announced that it will report results for the second quarter ended June 30, 2024, on Thursday, August …

EODHD | 18 July 2024

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

SAN DIEGO, July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and …

EODHD | 18 July 2024

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab)pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals …

EODHD | 18 July 2024
Support

Hi! How can we help you today?

Loading…